Evidence map›Paper›PMID 34171996›Full record

ArticleThe journal of headache and pain2021

Clinical relevance of depressed kynurenine pathway in episodic migraine patients: potential prognostic markers in the peripheral plasma during the interictal period.

Bernadett Tuka, Aliz Nyári, Edina Katalin Cseh, Tamás Körtési, Dániel Veréb, Ferenc Tömösi, Gábor Kecskeméti, Tamás Janáky, János Tajti, László Vécsei

Open access · goldAbstract read
In one paragraph

Article in The journal of headache and pain, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Glutamate as a Therapeutic Substrate in Migraine.International journal of molecular sciences · 2025
    Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Bernadett Tuka *Department of Neurology, Faculty of Medicine, University of Szeged, Semmelweis u 6, Szeged, H6725, Hungary.
Aliz Nyári *Department of Neurology, Faculty of Medicine, University of Szeged, Semmelweis u 6, Szeged, H6725, Hungary.
Edina Katalin CsehDepartment of Neurology, Faculty of Medicine, University of Szeged, Semmelweis u 6, Szeged, H6725, Hungary.
Tamás KörtésiDepartment of Neurology, Faculty of Medicine, University of Szeged, Semmelweis u 6, Szeged, H6725, Hungary.
Dániel VerébDepartment of Radiology, Faculty of Medicine, University of Szeged, Szeged, Hungary.
Ferenc TömösiDepartment of Medical Chemistry, Interdisciplinary Excellence Centre, University of Szeged, Szeged, Hungary.
Gábor KecskemétiDepartment of Medical Chemistry, Interdisciplinary Excellence Centre, University of Szeged, Szeged, Hungary.
Tamás JanákyDepartment of Medical Chemistry, Interdisciplinary Excellence Centre, University of Szeged, Szeged, Hungary.
János TajtiDepartment of Neurology, Faculty of Medicine, University of Szeged, Semmelweis u 6, Szeged, H6725, Hungary.
László VécseiDepartment of Neurology, Faculty of Medicine, University of Szeged, Semmelweis u 6, Szeged, H6725, Hungary. vecsei.laszlo@med.u-szeged.hu.
University of Szeged · HU

Funding

Hungarian Brain Research Program KTIA_13_NAP-A-III/9New National Excellence Program of the Ministry for Innovation and Technology UNKP-19-3TKP2020 Thematic Excellence Program 0T 204 2939/211TKP2020 Thematic Excellence Program NKFIH-1279-2/2020University of Szeged Open Access Fund 5108
6 · The paper itself

Abstract

backgroundAltered glutamatergic neurotransmission and neuropeptide levels play a central role in migraine pathomechanism. Previously, we confirmed that kynurenic acid, an endogenous glutamatergic antagonist, was able to decrease the expression of pituitary adenylate cyclase-activating polypeptide 1-38, a neuropeptide with known migraine-inducing properties. Hence, our aim was to reveal the role of the peripheral kynurenine pathway (KP) in episodic migraineurs. We focused on the complete tryptophan (Trp) catabolism, which comprises the serotonin and melatonin routes in addition to kynurenine metabolites. We investigated the relationship between metabolic alterations and clinical characteristics of migraine patients.

methodsFemale migraine patients aged between 25 and 50 years (n = 50) and healthy control subjects (n = 34) participated in this study. Blood samples were collected from the cubital veins of subjects (during both the interictal/ictal periods in migraineurs, n = 47/12, respectively). 12 metabolites of Trp pathway were determined by neurochemical measurements (UHPLC-MS/MS).

resultsPlasma concentrations of the most Trp metabolites were remarkably decreased in the interictal period of migraineurs compared to healthy control subjects, especially in the migraine without aura (MWoA) subgroup: Trp (p < 0.025), L-kynurenine (p < 0.001), kynurenic acid (p < 0.016), anthranilic acid (p < 0.007), picolinic acid (p < 0.03), 5-hydroxy-indoleaceticacid (p < 0.025) and melatonin (p < 0.023). Several metabolites showed a tendency to elevate during the ictal phase, but this was significant only in the cases of anthranilic acid, 5-hydroxy-indoleaceticacid and melatonin in MWoA patients. In the same subgroup, higher interictal kynurenic acid levels were identified in patients whose headache was severe and not related to their menstruation cycle. Negative linear correlation was detected between the interictal levels of xanthurenic acid/melatonin and attack frequency. Positive associations were found between the ictal 3-hydroxykynurenine levels and the beginning of attacks, just as between ictal picolinic acid levels and last attack before ictal sampling.

conclusionsOur results suggest that there is a widespread metabolic imbalance in migraineurs, which manifests in a completely depressed peripheral Trp catabolism during the interictal period. It might act as trigger for the migraine attack, contributing to glutamate excess induced neurotoxicity and generalised hyperexcitability. This data can draw attention to the clinical relevance of KP in migraine.

Indexed as

KynurenineTandem Mass SpectrometryAdultFemaleHumansKynurenic AcidMiddle AgedPituitary Adenylate Cyclase-Activating PolypeptidePrognosisKynurenic AcidKynureninePituitary Adenylate Cyclase-Activating PolypeptideAura-without auraClinical featuresEpisodic migraineInterictal-ictal periodsPlasma tryptophan metabolites: kynurenine-serotonin-melatonin pathways

Identifiers

PMID34171996
PMCPMC8229298
OpenAlexW3177467889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.